List view / Grid view

Sanofi

 

Sanofi reports positive Phase 3 results for Toujeo®

19 June 2014 | By Sanofi

Sanofi announced that, in a pooled analysis, investigational therapy Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia)...